aTyr Pharma (NASDAQ:ATYR – Get Free Report) is one of 846 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare aTyr Pharma to related companies based on the strength of its analyst recommendations, risk, institutional ownership, valuation, earnings, dividends and profitability.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for aTyr Pharma and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| aTyr Pharma | 1 | 0 | 1 | 1 | 2.67 |
| aTyr Pharma Competitors | 9775 | 15008 | 45291 | 1577 | 2.54 |
As a group, “Biotechnology” companies have a potential upside of 95.35%. Given aTyr Pharma’s rivals higher possible upside, analysts clearly believe aTyr Pharma has less favorable growth aspects than its rivals.
Valuation and Earnings
This table compares aTyr Pharma and its rivals gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| aTyr Pharma | $190,000.00 | -$74.12 million | -8.66 |
| aTyr Pharma Competitors | $712.90 million | $12.19 million | -10.14 |
aTyr Pharma’s rivals have higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 5.0% of aTyr Pharma shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Volatility and Risk
aTyr Pharma has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, aTyr Pharma’s rivals have a beta of 1.11, indicating that their average share price is 11% more volatile than the S&P 500.
Profitability
This table compares aTyr Pharma and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| aTyr Pharma | N/A | -95.89% | -69.67% |
| aTyr Pharma Competitors | -9,054.47% | -198.89% | -30.64% |
Summary
aTyr Pharma rivals beat aTyr Pharma on 7 of the 12 factors compared.
About aTyr Pharma
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
